Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

FAMOTIDINE 40 MG/5 ML SUSP

famotidine
$0.1434per ML

Strength

40 mg/5mL

Manufacturer

Zydus Pharmaceuticals (USA) Inc.

NDC

68382044405

Classification

Generic

Dosage Form

POWDER, FOR SUSPENSION

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

FAMOTIDINE

Approval Type

Generic (ANDA)

FDA Application

ANDA091020

On Market Since

4/22/2021

Pharmacological Classes

Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist

Price History

1W

0.0%

1M

-7.1%

3M

-28.2%

6M

-30.3%

1Y

-47.8%

3Y

-78.0%

5Y

-82.0%

All

-85.5%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

FAMOTIDINE 20 MG TABLET
Generic
63739064510•McKesson
$0.0303
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572860•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572870•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572880•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00904719306•Major Pharmaceuticals
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00904719361•Major Pharmaceuticals
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
31722001701•Camber Pharmaceuticals Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
31722001710•Camber Pharmaceuticals Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
50268029915•AvPAK
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
55111011901•Dr. Reddy's Laboratories Inc.
$0.0310
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy